Biofrontera Inc. BFRI 深 沪
等待开盘 12-19 09:30:00 美东时间
0.7605
+0.040
+5.61%
华盛通- 最 高0.8197
- 今 开0.785
- 成交量 23.46万股
- 最 低 0.7013
- 昨 收 0.7201
- 总市值 885.85万
- 52周最高 1.87
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.536
- 委 比 -99.81%
- 总股本 1164.83万
- 历史最高 292.60
- 量 比 4.11
- 振 幅 16.44%
- 历史最低 0.536
- 每 手 1
- 风险率 0.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biofrontera Transfers Of Ameluz, RhodoLED New Drug Applications, Investigational New Drug Applications; Completes Requirements For Transfer Of All U.S., Some Global Intellectual Property Associated With Ameluz And RhodoLED
Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced the completion of the transfer of the FDA approvals for
12-18 21:54
Biofrontera Files sNDA For Ameluz-PDT To Treat sBCC After Phase 3 Trial Achieves 65.5% Complete Clearance Of Main Target Lesions; Primary And Key Secondary Endpoints Met With High Statistical Significance With Favorable One-Year Recurrence and Aesthetic Outcomes
sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase 3 PDT study in patients with sBCC in the United States submitted to FDAPrimary and key
12-02 21:48
Biofrontera Q3 EPS $(0.62) Misses $(0.58) Estimate, Sales $6.988M Miss $7.000M Estimate
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.58) by 6.9 percent. This is a 36.73 percent increase over losses of $(0.98) per share from the
11-13 05:43
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
11-12 19:11
Biofrontera Earnings Preview
Biofrontera (NASDAQ:BFRI) is gearing up to announce its quarterly earnings on W...
11-12 03:03
Biofrontera Regains Nasdaq Compliance in November 2025
Biofrontera ( ($BFRI) ) has provided an update. Biofrontera Inc. has announced ...
11-11 06:19
Biofrontera Completes Sale of Xepi US License
The latest announcement is out from Biofrontera ( ($BFRI) ). On November 6, 202...
11-07 21:29
EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch
Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology product offerings.
11-07 20:52
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
Biofrontera Inc. has sold its U.S. rights to Xepi® (ozenoxacin) Cream, 1%, to Pelthos Therapeutics Inc., receiving $3 million upfront, $1 million upon commercial availability, and up to $6 million in milestones tied to sales targets. Proceeds will strengthen Biofrontera’s cash position and support growth of its photodynamic therapy platform and Ameluz® expansion. The transaction enables the company to focus on PDT development and profitability. X...
11-07 13:00
Biofrontera Finalizes U.S. Rights Acquisition Deal
Biofrontera ( ($BFRI) ) has shared an update. On October 20, 2025, Biofrontera ...
10-25 05:48
